This makes the site run faster and easier to use. Unfortunately, your browser is out of date and will not support some of these technologies.
We recommend that you use a modern browser such as Google Chrome or Microsoft Edge to view this website.
The COVID-19 outbreak is now increasing the need for healthcare professionals to advocate self-monitoring to reduce face-to-face consultations for pregnant and postnatal women whilst maintaining care for the woman and her baby.
Invented in the NHS for the NHS, as a direct response to a clinical need. Designed by clinicians to be faster than pen and paper.
Listed on NHS Digital Apps Library. NICE approval expected imminently.
Self-management, combined with remote monitoring, gives pregnant women greater control of their diabetes and reduces the number of clinic visits.
Improves the efficiency of the workflow by streamlining the process of communication between midwives and patients.
Anonymised patient data is securely stored on the cloud as a completely isolated instance with HSCN connectivity and rigorous data security and privacy.
Electronic capture of data enables detailed auditing of care and outcomes while supporting clinical governance.
This product is classified as a Class I medical device that complies with the essential requirements of Directive 93/42/EEC and following amendments.
Note: Not all Sensyne Health products are available in all territories, for further information contact head office.
The GDm-Health system comprises a smartphone app which connects to a wireless blood glucose (BG) meter using Bluetooth or NFC (Near Field Communication).
A woman’s measurements, along with any text-based commentary she wishes to log for call back, is then transmitted directly to a clinical dashboard for the multi-disciplinary team to proactively manage.
GDm-Health enables clinicians to see at a glance, near real-time blood glucose readings and prioritise care to women most in need whilst maintaining at a glance oversight of all patient cohorts.
GDm-Health improves the efficiency of the workflow by streamlining the process of communication between midwives and women. Communication between healthcare professionals through the patient’s GDM tailored digital record enhances team-based care.
“Feedback from women using GDm-Health has been very positive. They like to know that their condition is being monitored, and appreciate the immediate feedback when their condition requires intervention from a clinician. It is particularly beneficial to women whose first language is not English, or who struggle with literacy. Being able to use an app rather than a handwritten log book and emails suits the current pregnant population – the millennial, but is very easy for everyone to use.”
*Results did not reach statistical significance. Mackillop L, et al. JMIR Mhealth Uhealth 2018;6(3):e71
*Results did not reach statistical significance. Mackillop L, et al. JMIR Mhealth Uhealth 2018;6(3):e71
Significantly higher patient satisfaction with care
(P=.049)
Significantly better compliance with BG monitoring
Increased from 61% to 80% (P=.001)
(30 April 2019: 765)
(30 April 2019: 310)
(30 April 2019: 6,038)
(30 April 2019: 486)
1. Mackillop L, Hirst JE, Bartlett KJ, et al. Comparing the Efficacy of a Mobile Phone-Based Blood Glucose Management System With Standard Clinic Care in Women With Gestational Diabetes: Randomized Controlled Trial. JMIR Mhealth Uhealth. 2018;6(3):e71.
2. GDm-Health for people with gestational diabetes - Medtech innovation briefing [MIB131] Published date: 13 November 2017 https://www.nice.org.uk/advice/mib131
Comparing the Efficacy of a Mobile Phone-Based Blood Glucose Management System With Standard Clinic Care in Women With Gestational Diabetes
Randomized Controlled Trial
Read more
Novel Way to Deliver Care to Women with GDM through the Use of Cloud Technology
Conference Poster
Read more
Disclaimer: Sensyne Health is not responsible for external website content.
Note: Not all Sensyne Health products are available in all territories, for further information contact head office.
Sensyne may have access to anonymous non-personal data generated in connection with the GDm-Health App. This data is only used for medical research purposes or for product improvement.
© 2021 Sensyne Health plc. All rights reserved.
Sensyne Health Group Limited. registered in England and Wales No. 11240986 is a trading company of Sensyne Health plc registered in England and Wales No. 11425451
Registered office: Schrödinger Building, Heatley Road, Oxford Science Park, Oxford, OX4 4GE, United Kingdom.
Note: Not all Sensyne Health products are available in all territories, for further information contact head office.
In support of the ‘Understanding Patient Data’ initiative, Sensyne Health cite that its “work uses data provided by patients and collected by the NHS as part of their care and support”. #datasaveslives
